CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing clinical trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in the individualization of care for patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate cancer treatment algorithms on the basis of new data sets and the perspectives of clinical investigators specializing in particular tumor types.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Kenneth C Anderson, MD
  Director, Jerome Lipper Multiple Myeloma Center
  Dana-Farber Cancer Institute
  Kraft Family Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc; Consulting Agreements: Mana Therapeutics, Precision BioSciences, Raqia Therapeutics Inc, WindMIL Therapeutics; Scientific Founder: C4 Therapeutics, OncoPep.
  
  Joaquim Bellmunt, MD, PhD
  Director, Bladder Cancer Program
  Beth Israel Deaconess Medical Center
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Pfizer Inc; Contracted Research: Merck, Pfizer Inc, Takeda Oncology.
  
  D Ross Camidge, MD, PhD
  Professor of Medicine/Oncology
  Joyce Zeff Chair in Lung Cancer Research
  Director of Thoracic Oncology
  University of Colorado, Anschutz Medical Campus
  Denver, Colorado
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Lilly, Mersana Therapeutics, OnKure, Pfizer Inc, Qilu Pharmaceutical Co Ltd, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bio-Thera Solutions; ILD Adjudication Committee: Daiichi Sankyo Inc; Scientific Advisory Board: Amgen Inc, Anchiano Therapeutics, Apollomics Inc, Elevation Oncology, Kestrel, Nuvalent.
  
  Harry Paul Erba, MD, PhD
  Director, Leukemia Program
  Instructor in the Department of Medicine
  Member of the Duke Cancer Institute
  Duke University School of Medicine
  Durham, North Carolina
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Oncology, Trillium Therapeutics Inc. Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.
  
  Rami Komrokji, MD
  Senior Member and Section Head for Leukemia and MDS
  Vice Chair, Department of Malignant Hematology
  Moffitt Cancer Center
  Professor of Oncologic Sciences
  Morsani College of Medicine, University of South Florida
  Tampa, Florida
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Innovent, Novartis, PharmaEssentia, Taiho Oncology Inc; Consulting Agreements: AbbVie Inc, Acceleron Pharma, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Geron, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Jazz Pharmaceuticals Inc.
  
  Benjamin Levy, MD
  Associate Professor, Johns Hopkins School of Medicine
  Clinical Director
  Medical Director, Thoracic Oncology Program
  Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
  Washington, DC
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck.
  
  Wells A Messersmith, MD
  Professor and Head, Division of Medical Oncology
  Associate Director for Translational Research
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Contracted Research: ALX Oncology, BeiGene Ltd, Bristol-Myers Squibb Company, Exelixis Inc, Experimental Drug Development Centre (Singapore), Immunomedics Inc, Pfizer Inc, Mitsubishi Tanabe Pharma America; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics, Zymeworks.
  
  Craig Moskowitz, MD
  Physician in Chief, Oncology Service Line
  Sylvester Comprehensive Cancer Center
  Professor of Medicine, Miller School of Medicine
  University of Miami Health System
  Miami, Florida
  
  Contracted Research: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Seagen Inc; Scientific Advisory Board: AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Molecular Templates, Seagen Inc, Takeda Oncology.
  
  Ruth O'Regan, MD
  Chair, Department of Medicine
  Charles A Dewey Professor of Medicine
  University of Rochester
  Rochester, New York
  
  Advisory Committee and Consulting Agreements: bioTheranostics Inc, Cyclacel Pharmaceuticals Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Contracted Research: Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Immunomedics Inc.
  
  Eileen M O'Reilly, MD
  Winthrop Rockefeller Endowed Chair in Medical Oncology
  Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
  Co-Director, Medical Initiatives
  David M Rubenstein Center for Pancreatic Cancer Research
  Attending Physician, Member
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine, Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, CytomX Therapeutics, Debiopharm Group, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Gilead Sciences Inc, HelioHealth, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MiNA Therapeutics, Polaris Group, QED Therapeutics, RedHill Biopharma Ltd, Silenseed Ltd, SillaJen, Sobi, TheraBionic, twoXAR, Vector Pharma, Yiviva; Contracted Research: Acta Biológica, Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Bristol-Myers Squibb Company, CASI Pharmaceuticals Inc, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Halozyme Inc, Incyte Corporation, MabVax Therapeutics, Puma Biotechnology Inc, QED Therapeutics, SillaJen, Yiviva.
  
  Sumanta Kumar Pal, MD
  Clinical Professor, Department of Medical Oncology and Therapeutics Research
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  No relevant conflicts of interest to disclose.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.
  
  Jeff Sharman, MD
  Medical Director of Hematology Research
  US Oncology Network
  Willamette Valley Cancer Institute and Research Center
  Eugene, Oregon
  
  Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.
  
  Tiffany A Traina, MD
  Vice Chair, Oncology Care
  Section Head, Triple-Negative Breast Cancer Clinical Research Program
  Associate Attending Physician
  Breast Medicine Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  Associate Professor
  Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: Aduro Biotech, Advaxis Inc, AstraZeneca Pharmaceuticals LP, Athenex Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Exact Sciences Inc, Genentech, a member of the Roche Group, Halozyme Inc, Innocrin Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Merck, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Innocrin Pharmaceuticals Inc, Novartis, Pfizer Inc; Speakers Bureau: Genentech, a member of the Roche Group.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Daiichi Sankyo Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Lilly, Merck, Novartis, Oncopeptides, Sanofi Genzyme, Seagen Inc, and Taiho Oncology Inc.
  
  Release date: June 2021
  Expiration date: June 2022